ArticleJournal of applied genetics2026
The methylation of LHX2, RAPGEFL1, RARB and RYR2 has prognostic significance in head and neck squamous cell carcinoma patients.
Article in Journal of applied genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Head and neck squamous cell carcinomas (HNSCC) are a group of frequently occurring tumors with a high rate of relapse and 5-year survival of approximately 60%. Novel diagnostic and prognostic biomarkers analyzed in liquid biopsy could improve clinical management of patients and prolong their survival. Thus, the aim of this study was to evaluate the utility of DNA methylation analysis in the clinical management of HNSCC patients. Based on our previous studies and the analysis of TCGA data, we selected six epigenetically regulated genes, which differentiated HNSCC patients from healthy controls. Next, we used a two-step nested MethyLight assay to analyze the DNA methylation of DAPK1, LHX2, MGMT, RAPGEFL1, RARB, and RYR2 in HNSCC tumor samples, which was followed by confirmatory analysis of cfDNA from plasma samples in another cohort of HNSCC patients. We provided evidence for the relevance of DAPK1, LHX2, MGMT, RAPGEFL1, RARB, and RYR2 methylation analysis in HNSCC diagnosis. Importantly, the methylation of RAPGEFL1, RARB, and RYR2 in tumor samples was found to be associated with HNSCC recurrence. The presence of methylation of RARB and LHX2 in cfDNA distinguished HNSCC patients from healthy controls. Overall, we report that LHX2, RAPGEFL1, RARB, and RYR2 are promising candidates for a methylation-based diagnostic tool in HNSCC patients.
Indexed as
Identifiers
41766007What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.